ABEONA THERAPEUTICS INC (ABEO) Stock Overview
USA - NASDAQ:ABEO - US00289Y2063 - Common Stock
ABEO Key Statistics, Chart & Performance
The current stock price of ABEO is 5.47 USD. In the past month the price decreased by -0.73%. In the past year, price decreased by -15.85%.
ABEO Latest News, Press Relases and Analysis
ABEO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.85 | 408.76B | ||
| AMGN | AMGEN INC | 13.81 | 162.12B | ||
| GILD | GILEAD SCIENCES INC | 16.03 | 153.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.16 | 109.29B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.69 | 61.40B | ||
| ARGX | ARGENX SE - ADR | 90.64 | 51.39B | ||
| INSM | INSMED INC | N/A | 34.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.1 | 34.68B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.70B | ||
| NTRA | NATERA INC | N/A | 25.65B | ||
| BIIB | BIOGEN INC | 9.13 | 21.44B |
Related stock screener links
About ABEO
Company Profile
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in Cleveland, Ohio and currently employs 136 full-time employees. The firm's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Company Info
ABEONA THERAPEUTICS INC
6555 Carnegie Ave, 4th Floor
CLEVELAND OHIO 75219 US
CEO: Michael Amoroso
Employees: 136
Phone: 16468134701
ABEONA THERAPEUTICS INC / ABEO FAQ
What is the stock price of ABEONA THERAPEUTICS INC today?
The current stock price of ABEO is 5.47 USD. The price decreased by -0.55% in the last trading session.
What is the ticker symbol for ABEONA THERAPEUTICS INC stock?
The exchange symbol of ABEONA THERAPEUTICS INC is ABEO and it is listed on the Nasdaq exchange.
On which exchange is ABEO stock listed?
ABEO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ABEONA THERAPEUTICS INC stock?
12 analysts have analysed ABEO and the average price target is 20.91 USD. This implies a price increase of 282.27% is expected in the next year compared to the current price of 5.47. Check the ABEONA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ABEONA THERAPEUTICS INC worth?
ABEONA THERAPEUTICS INC (ABEO) has a market capitalization of 280.50M USD. This makes ABEO a Micro Cap stock.
How many employees does ABEONA THERAPEUTICS INC have?
ABEONA THERAPEUTICS INC (ABEO) currently has 136 employees.
What are the support and resistance levels for ABEONA THERAPEUTICS INC (ABEO) stock?
ABEONA THERAPEUTICS INC (ABEO) has a support level at 5.47 and a resistance level at 5.48. Check the full technical report for a detailed analysis of ABEO support and resistance levels.
Is ABEONA THERAPEUTICS INC (ABEO) expected to grow?
The Revenue of ABEONA THERAPEUTICS INC (ABEO) is expected to grow by 27374.5% in the next year. Check the estimates tab for more information on the ABEO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ABEONA THERAPEUTICS INC (ABEO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ABEO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ABEO, evaluating the profitability, health, valuation and growth aspects
- ABEONA THERAPEUTICS INC (ABEO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ABEONA THERAPEUTICS INC (ABEO) Sales and EPS estimates to see what analysts future expectations are.
- ABEONA THERAPEUTICS INC (ABEO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ABEONA THERAPEUTICS INC (ABEO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ABEONA THERAPEUTICS INC (ABEO) Stock Chart to make your own analysis
- ABEONA THERAPEUTICS INC (ABEO) Latest news and press-releases to stay up to date.
Does ABEONA THERAPEUTICS INC (ABEO) stock pay dividends?
ABEO does not pay a dividend.
When does ABEONA THERAPEUTICS INC (ABEO) report earnings?
ABEONA THERAPEUTICS INC (ABEO) will report earnings on 2025-11-12.
What is the Price/Earnings (PE) ratio of ABEONA THERAPEUTICS INC (ABEO)?
ABEONA THERAPEUTICS INC (ABEO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.54).
What is the Short Interest ratio of ABEONA THERAPEUTICS INC (ABEO) stock?
The outstanding short interest for ABEONA THERAPEUTICS INC (ABEO) is 18.08% of its float. Check the ownership tab for more information on the ABEO short interest.
ABEO Technical Analysis
ABEO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABEO. ABEO has a bad profitability rating. Also its financial health evaluation is rather negative.
ABEO Financial Highlights
Over the last trailing twelve months ABEO reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS increased by 30.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14310.5% | ||
| ROA | 23.25% | ||
| ROE | 34.99% | ||
| Debt/Equity | 0.09 |
ABEO Forecast & Estimates
12 analysts have analysed ABEO and the average price target is 20.91 USD. This implies a price increase of 282.27% is expected in the next year compared to the current price of 5.47.
For the next year, analysts expect an EPS growth of 174.57% and a revenue growth 27374.5% for ABEO